SEC Form 4 · accession 0001179110-17-010365
Nabriva Therapeutics Legacy plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Period of report
Jul 11, 2017
Accepted (ET)
Jul 13, 2017 · 9:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001703287
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jul 11, 2017 | S | 3,521 | $10.5161 | D | 2,565,661 | D | |
| Ordinary SharesF2 | Jul 12, 2017 | S | 13,740 | $10.5001 | D | 2,551,921 | D | |
| Ordinary SharesF3 | Jul 13, 2017 | S | 39,914 | $10.5416 | D | 2,512,007 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $10.50 to $10.59 Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price.
- F2The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $10.50 to $10.52 Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price.
- F3The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price.